Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID program to improve prostate cancer diagnosis across South West London. In addition to the six high-resolution Arietta ultrasound systems, the contract also includes six BiopSee image-guided fusion biopsy systems from MedCom (for which Hitachi is a European distributor) to be installed at three major hospitals. Using the two systems together will allow providers to combine multiparametric magnetic resonance imaging (mp-MRI) data with real-time ultrasound, reducing unnecessary biopsies and providing accurate targeting while reducing the number of samples needed.

June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis has begun treating patients with Viewray's second-generation magnetic resonance (MR) image-guided radiotherapy system, the MRIdian Linac. Siteman is the first U.S. cancer center to offer cancer therapy with both MRIdian and MRIdian Linac.

Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a broad patent for its artificial intelligence (AI) computed tomography (CT) technology. The technology in question forms a vessel suppressed, chest CT series using deep learning and synthetic data modeling. The company said the patent holds promise for improving the detection and diagnosis of lung cancer at an earlier stage while making clinicians more efficient, a first for computer-aided detection (CAD).

This is a 360 degree image from the Canon Aquilion 64-slice computed tomography (CT) system installed at Northwestern Medicine Central DuPage Hospital in Winfield, Ill.  The room is large, allowing for gurney access on either side of the scanner. The two-part door to the hall also can open to allow better access.

EOS imaging announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its hipEOS 3.0 surgical planning software.

Artificial intelligence (AI) platform provider EnvoyAI recently completed their first successful customer installation at Wake Radiology in Raleigh, N.C. Wake Radiology is using the platform to provide physicians access to EnvoyAI’s growing marketplace of over 53 AI engines that may be applied to their medical imaging studies. Wake Radiology selected EnvoyAI as the fastest and most comprehensive means to achieving a complete AI strategy for the diverse breadth of clinical services that it provides for patients and referring physicians.

A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission tomography/computed tomography (PET/CT) imaging on patient management of biochemically recurrent prostate cancer after initial prostate cancer treatment and negative or equivocal findings on standard-of-care imaging. The LOCATE trial is a prospective, multi-center, open-label study (NCT02680041) conducted at 15 sites in the United States. Its primary endpoint measured the percentage of men with suspected biochemical recurrence of prostate cancer following initial prior therapy whose treatment plan was changed following an 18F fluciclovine PET/CT scan.

Peter Chang, M.D., current neuroradiology fellow at UCSF and recently recruited co-director of the UCI Center for Artificial Intelligence in Diagnostic Medicine (CAIDM), is the honorary recipient of the Cornelius G. Dyke Memorial Award. The award was given by the American Society of Neuroradiology (ASNR) for Chang’s work in developing a customized deep learning system with over 97 percent accuracy in near real-time detection of hemorrhage on non-contrast computed tomography (NCCT) exam of the head.

Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery of total body irradiation (TBI). TBI is a procedure commonly used to prepare patients being treated for leukemia and multiple myeloma for a bone marrow transplant. It involves irradiation of the entire body, elevating the need for precision, accuracy and homogeneity in radiation dose delivery. The TomoTherapy platform's architecture enables efficient and effective delivery of radiation over large areas of the patient, making it a valuable part of the bone marrow transplantation conditioning regimen.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now